Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Peptides ; 18(2): 269-75, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9149300

RESUMO

The effect of vasoactive intestinal peptide (VIP) on the nerve-stimulated contraction, tissue oxygenation, lipid peroxidation and antioxidant enzymes activities-superoxide dismutase and catalase was investigated in the rat gastrocnemius muscle exposed to 4 h ischemia-4hr reperfusion. Ischemia caused significant decrease in muscle contractile force, oxygenation and superoxide dismutase enzyme activity. Reperfusion of ischemic muscle increased the muscle contractile force and restored the tissue oxygenation to the baseline level. Superoxide dismutase and catalase activities of reperfused muscle increased significantly. However neither ischemia nor reperfusion affected gastrocnemius muscle malondialdehide (MDA) levels. VIP administration at the onset of reperfusion significantly increased skeletal muscle contractile force and tissue oxygenation even higher than baseline and reperfusion values. VIP also normalized the increased superoxide dismutase and catalase activities of reperfused skeletal muscle. In conclusion, VIP, acting as a powerful antioxidant and preserving contractile machinery seems to be a promising endogenous peptide that can salvage the skeletal muscle from severe ischemia-reperfusion injury.


Assuntos
Catalase/metabolismo , Isquemia/fisiopatologia , Contração Muscular/efeitos dos fármacos , Músculo Esquelético/irrigação sanguínea , Consumo de Oxigênio/efeitos dos fármacos , Superóxido Dismutase/metabolismo , Peptídeo Intestinal Vasoativo/farmacologia , Análise de Variância , Animais , Masculino , Malondialdeído/metabolismo , Músculo Esquelético/fisiologia , Músculo Esquelético/fisiopatologia , Ratos , Ratos Wistar , Reperfusão , Fatores de Tempo
2.
Eur J Med Res ; 9(12): 570-2, 2004 Dec 22.
Artigo em Inglês | MEDLINE | ID: mdl-15689305

RESUMO

Hashimoto thyroiditis (HT), which is an autoimmune disease of thyroid gland, has been declared to present with concomitant several systemic diseases. In this study, the coexistence of the Hashimoto disease with the sleep apnea syndrome has been examined. Seven female patients (33-66 year of age) with Hashimoto thyroiditis were evaluated for sleep apnea syndrome. The diagnosis of Hashimoto disease was based on the high titers of anti-thyroid antibodies and histological findings. None of the patients had any complaints of sleep disturbances. Seven healthy subjects with similar age and sex characteristics were taken as the control group. All the patients and the control subjects were undertaken a full polysomnography (PSG). Five patients with HT showed the characteristics of obstructive sleep apnea syndrome (one severe, one moderate and three mild OSAS), whereas no sleep breathing disturbance was found in the control group. These findings suggest that sleep related breathing problems may develop in the patients with autoimmune thyroiditis even if they are euthyroid.


Assuntos
Apneia Obstrutiva do Sono/etiologia , Tireoidite Autoimune/complicações , Adulto , Idoso , Feminino , Humanos , Pessoa de Meia-Idade , Apneia Obstrutiva do Sono/fisiopatologia
3.
Indian J Physiol Pharmacol ; 45(1): 54-62, 2001 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-11211571

RESUMO

The roles of cGMP, prostaglandins, the entry of extracellular Ca2+ through slow channels, endothelium and V1 receptors in the negative inotropic, chronotropic and coronary vasoconstrictor responses to arginine vasopressin (AVP) have been investigated in isolated perfused rat hearts. The bolus injection of 5 x 10(-5) M AVP produced a significant decrease in contractile force, heart rate and coronary flow. AVP also significantly decreased contractile force, heart rate and coronary flow in hearts pretreated with an inhibitor of soluble guanylate cyclase methylene blue (10(-6) M), an effective drug for removing endothelium saponin (500 micrograms/ml), an inhibitor of cyclooxygenase indomethacin (10(-5) M) or a calcium channel antagonist verapamil (5 x 10(-7) M). The potent V1 receptor antagonist [Deamino-Pen1, Val4, D-Arg8]-vasopressin (9 x 10(-5) M) did not alter effects of AVP but the very potent V1 receptor antagonist [beta-Mercapto-beta, beta-cyclopentamethylene-propionyl1, O-Me-Tyr2, Arg8]-vasopressin (8 x 10(-5) M) abolished these effects. Our results suggest that AVP produces negative inotropic, chronotropic and coronary vasoconstrictor effects in isolated perfused rat hearts. cGMP, prostaglandin release and Ca2+ entry does not involve in the effects of AVP. These effects are endothelium independent and mediated by V1 receptors. The use of V1 receptor antagonist [beta-mercapto-beta, beta-cyclopentamethylene-propionyl1, O-Me-Tyr2, Arg8]-vasopressin may be beneficial for preventing the negative inotropy, chronotropy and coronary vasoconstriction induced by AVP.


Assuntos
Circulação Coronária/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Coração/efeitos dos fármacos , Contração Miocárdica/efeitos dos fármacos , Vasoconstritores/farmacologia , Vasopressinas/farmacologia , Animais , Circulação Coronária/fisiologia , Feminino , Coração/fisiologia , Frequência Cardíaca/fisiologia , Masculino , Contração Miocárdica/fisiologia , Ratos , Ratos Wistar , Receptores de Vasopressinas/efeitos dos fármacos , Receptores de Vasopressinas/fisiologia
5.
Acta Physiol Hung ; 85(2): 163-74, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9706311

RESUMO

The role of nitric oxide (NO) in the regulation of coronary flow and mechanical function under basal conditions and when exposed to nifedipine was studied in perfused rat hearts. Inhibition of basal release of NO by bolus injections of NG-nitro-L-arginine (L-NNA) (90 mM) and NG-nitro-L-arginine methyl ester (L-NAME) (185, 370 and 740 mM) induced significant decrease in coronary flow, contractile force and heart rate. L-NAME in the doses of 185, 370 and 740 mM also decreased significantly contractile force and heart rate during treatment with 170 microM nifedipine. However, the same doses of L-NAME caused an insignificant reduction in coronary flow in the presence of nifedipine. These findings suggest that NO has an important role in the regulation of coronary flow and mechanical performance under basal conditions and during the hearts exposed to nifedipine. Nifedipine may attenuate the myocardial ischaemia induced by the loss of NO production.


Assuntos
Circulação Coronária/fisiologia , Contração Miocárdica/fisiologia , Óxido Nítrico/fisiologia , Animais , Circulação Coronária/efeitos dos fármacos , Inibidores Enzimáticos/administração & dosagem , Feminino , Frequência Cardíaca/efeitos dos fármacos , Frequência Cardíaca/fisiologia , Técnicas In Vitro , Masculino , Contração Miocárdica/efeitos dos fármacos , NG-Nitroarginina Metil Éster/administração & dosagem , Nifedipino/farmacologia , Óxido Nítrico Sintase/antagonistas & inibidores , Nitroarginina/administração & dosagem , Perfusão , Ratos , Ratos Wistar
6.
Med Princ Pract ; 12(3): 184-8, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12766338

RESUMO

OBJECTIVE: This study was undertaken to investigate the prevalence of HBsAg, anti-HBs and anti-HCV positivity in Istanbul, Turkey. SUBJECTS AND METHODS: The frequencies of HBsAg, anti-HBs and anti-HCV positivity were determined in 1,157 randomly selected patients attending the outpatient clinic of Istanbul University Hospital, Istanbul, Turkey, during the years 1998 and 2001. All patients underwent complete physical and various routine laboratory examinations. RESULTS: Of the 1,157 patients, the prevalence of HBsAg, anti-HBs and anti-HCV was 6.6, 28.1 and 2.4%, respectively. It appeared that having dental and surgical procedures formed the risk factors for HBV infection. HBsAg positivity in the health care workers was not different from that of the other professions, but anti-HBs was significantly higher in this group. CONCLUSIONS: Our findings indicate that HBV infection occurs more frequently than HCV in Istanbul, and this poses an important health problem in the community.


Assuntos
Anticorpos Anti-Hepatite B/sangue , Antígenos de Superfície da Hepatite B/sangue , Hepatite B/epidemiologia , Anticorpos Anti-Hepatite C/sangue , Hepatite C/epidemiologia , Adolescente , Adulto , Distribuição por Idade , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Feminino , Pessoal de Saúde/estatística & dados numéricos , Hepatite B/sangue , Hepatite B/imunologia , Hepatite C/sangue , Hepatite C/imunologia , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Características de Residência , Fatores de Risco , Estudos Soroepidemiológicos , Turquia/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA